JPMorgan Cautions Hims & Hers on GLP-1 Market Transition

By EC Assets · Published 11 September 2026

JPMorgan Chase expressed caution regarding Hims & Hers due to potential risks associated with the company's transition into the GLP-1 market. Hims & Hers is expanding its GLP-1 offerings. The company aims to leverage its wellness subscription thesis. Hims & Hers has already transitioned to branded GLP-1 products. This move drives robust engagement and subscriber growth. It also triggered the raised fiscal year 2026 guidance and reiterated fiscal year 2030 guidance. The company's expansion includes strategic acquisitions in Canada and the European Union. Hims & Hers CEO Andrew Dudum projects that prices of GLP-1 drugs could fall to $40-$50. The company has expanded its GLP-1 offerings with a Novo Nordisk deal and an acquisition of Eucalyptus. Hims & Hers is also making a push into the Canadian GLP-1 market. CEO Andrew Dudum also defended his company against a recent Federal Trade Commission lawsuit during a CNBC interview. This article is intended for informational purposes only. It does not constitute investment advice.